Á lódáil...
Selection pressure exerted by imatinib therapy leads to disparate outcomes of imatinib discontinuation trials
BACKGROUND: Chronic myeloid leukemia is successfully managed by imatinib therapy, but the question remains whether treatment must be administered indefinitely. Imatinib discontinuation trials have led to two distinct outcomes: about 60% of patients experienced disease relapse within 6 months of trea...
Na minha lista:
| Main Authors: | , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
Ferrata Storti Foundation
2012
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3487556/ https://ncbi.nlm.nih.gov/pubmed/22419579 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3324/haematol.2012.062844 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|